Valuation: Mabion S.A.

Market Cap 123M 32.36M 28.19M 26.63M 24.3M 45.33M 3.1B 45.43M 318M 1.58B 122M 119M 5.08B P/E 2024
-22.7x
P/E 2025 -1.8x
Enterprise Value 129M 34.02M 29.63M 28M 25.55M 47.66M 3.26B 47.76M 334M 1.66B 128M 125M 5.34B EV / Sales 2024
1,574,345x
EV / Sales 2025 7,560,388x
Free-Float
67.18%
Yield 2024 *
-
Yield 2025 -
1 day-2.93%
1 week-0.26%
Current month-2.69%
1 month-0.39%
3 months-1.55%
6 months-13.72%
Current year+9.03%
1 week 7.61
Extreme 7.61
8.12
1 month 7.6
Extreme 7.6
8.47
Current year 7.01
Extreme 7.01
10
1 year 6.7
Extreme 6.7
10
3 years 6.7
Extreme 6.7
23.6
5 years 6.7
Extreme 6.7
110
10 years 6.7
Extreme 6.7
139
Manager TitleAgeSince
Chief Executive Officer - -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Director TitleAgeSince
Director/Board Member - 23/02/2021
Chairman 60 13/05/2021
Director/Board Member 53 -
Change 5-day change 1-year change 3-year change Capi.($)
-2.93%-0.26%-18.17%-56.14% 32.32M
-0.31%+5.79%+47.13%+99.00% 70.88B
+0.39%+2.06%+39.38%+78.27% 62.49B
+0.50%+7.13%+33.27%+16.01% 26.34B
-3.21%-7.27%-17.10%+356.10% 26.21B
-2.64%-0.69%-0.17%-13.01% 24.13B
+0.71%+8.03%+25.03%-12.74% 20.72B
+2.12%-5.86%+161.58%+329.34% 15.36B
-0.22%+3.99%+45.54%+172.46% 14.46B
+0.73%+1.71%-5.51%+849.47% 14.24B
Average -0.49%+1.54%+31.10%+181.88% 27.49B
Weighted average by Cap. -0.28%+1.49%+35.68%+148.20%

Financials

2024 2025
Net sales 69.02 18.16 15.82 14.94 13.64 25.44 1.74K 25.49 178.47 886.22 68.21 66.82 2.85K 15.76 4.15 3.61 3.41 3.11 5.81 397.65 5.82 40.74 202.32 15.57 15.25 651.12
Net income -6.33M -1.67M -1.45M -1.37M -1.25M -2.33M -160M -2.34M -16.38M -81.33M -6.26M -6.13M -262M -62.61M -16.47M -14.35M -13.56M -12.37M -23.08M -1.58B -23.13M -162M -804M -61.88M -60.62M -2.59B
Net Debt -35.18M -9.26M -8.06M -7.62M -6.95M -12.97M -888M -13M -90.98M -452M -34.77M -34.06M -1.45B 6.32M 1.66M 1.45M 1.37M 1.25M 2.33M 159M 2.33M 16.33M 81.1M 6.24M 6.11M 261M
Logo Mabion S.A.
Mabion SA is a Poland-based biopharmaceutical company. The Company provides a broad spectrum of services in the segment of small and medium-sized projects at various stages of development (from early-stage discovery to commercial manufacturing). The Company's competencies include the selection of protein expression technologies, their purification, GMP-standard manufacturing activities (obtaining Active Substances - Drug Substance and Finished Products - Drug Product), development of analytical tools (for structural, functional, physicochemical characterization), clinical development, clinical analytics and a full range of regulatory activities in the development and operational areas. The Company's goal is to establish itself as a recognizable player in the global contract manufacturing and contract drug development market and to complete its full transformation into an integrated biologics CDMO company.
Employees
202
Date Price Change Volume
18/09/26 PLN 7.610 -2.93% 55,791
17/09/26 PLN 7.840 -0.38% 25,277
16/09/26 PLN 7.870 -0.51% 11,134
15/09/26 PLN 7.910 -1.12% 18,972
14/09/26 PLN 8.000 +4.85% 74,056

Annual profits - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!